| |
Number
|
Before injection
|
7 d after injection
|
10 d after injection
|
12 d after injection
|
14 d after injection
|
|---|
|
Normal group
|
10
|
8.06 ± 0.71
|
8.22 ± 0.80
|
8.17 ± 0.75
|
8.19 ± 0.86
|
8.63 ± 0.53
|
|
PD group
|
10
|
8.46 ± 0.36
|
6.55 ± 0.63*
|
6.05 ± 0.35*
|
6.51 ± 0.81*
|
7.11 ± 0.68*
|
|
NC group
|
10
|
8.39 ± 0.70
|
6.56 ± 0.71*
|
6.09 ± 0.49*
|
6.55 ± 0.50*
|
7.06 ± 0.81*
|
|
miR-96 mimic group
|
10
|
8.07 ± 0.37
|
4.38 ± 0.74*#
|
4.23 ± 0.35*#
|
4.27 ± 0.27*#
|
5.54 ± 0.62*#
|
|
miR-96 inhibitor group
|
10
|
8.11 ± 0.16
|
3.22 ± 0.71*#
|
3.06 ± 0.44*#
|
3.19 ± 0.32*#
|
4.13 ± 0.59*#
|
|
CACNG5 group
|
10
|
8.25 ± 0.21
|
3.56 ± 0.17*#
|
3.41 ± 0.46*#
|
3.37 ± 0.18*#
|
4.15 ± 0.45*#
|
|
miR-96 mimic + CACNG5 group
|
10
|
8.30 ± 0.69
|
6.36 ± 0.66*
|
6.06 ± 0.73*
|
6.60 ± 0.78*
|
7.03 ± 0.67*
|
- Note: The test was repeated three times independently, and the one-way ANOVA analysis was used for comparison among multiple groups (n = 10)
- PD Parkinson disease, NC Negative control, miR-96 microRNA-96, CACNG5 Calcium voltage-gated channel auxiliary subunit gamma 5, d Day
- *P < 0.05 compared with the normal group, #, P < 0.05 compared with the PD group
